Skip to main content
Signal8
Launch Terminal

Xencor Inc (XNCR)

Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders. The company is associated with several notable therapies currently in use, such as Sotrovimab, which targets the SARS-CoV-2 virus; Ultomiris, prescribed for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi, indicated for individuals with relapsed or refractory diffuse large B-cell lymphoma. Xencor maintains a robust and diverse pipeline of drug candidates advancing through various clinical trial stages. In oncology, this includes Plamotamab, a tumor-targeted antibody, currently undergoing Phase I trials for non-Hodgkin lymphoma; Vudalimab, a bispecific antibody in Phase II for metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab, also in Phase II for neuroendocrine tumors. Further cancer-focused programs comprise XmAb306, XmAb104, and XmAb841, all in Phase I for selected solid tumors; AMG 509, in Phase I for prostate cancer; XmAb819, being developed for renal cell carcinoma; and a program involving Novartis XmAb. In the infectious disease arena, Xencor is progressing VIR-3434 through Phase II for hepatitis B virus infection; VIR-2482 in Phase 1/2 for influenza A; VIR-7832 in a Phase 1b/2a trial for mild-to-moderate COVID-19; and is involved in the Phase 2/3 NIH ACTIV-2 trial for COVID-19 with BMS-986414 + BMS-986413. Beyond these, the company is developing XmAb564, a Phase I candidate for autoimmune diseases; Obexelimab, also for autoimmune conditions; AIMab7195, designed to reduce IgE levels for allergic responses; and Xpro1595, an experimental treatment for Alzheimer's disease, mild cognitive impairment, and depression. Xencor also holds a licensing agreement with Caris Life Sciences.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Xencor, Inc. logo

Xencor, Inc.

NASDAQ:XNCRHealthcare
+2.09%$29.82
AH$30.10+0.94%vs close
Mkt Cap$2.22B
Float72.26M
O/S74.35M
Vol
$ Vol
RVOL
Inst Own-
SI17.0%
Earnings
Dilution
Xencor, Inc. logoNASDAQ:XNCR$29.82+2.09%
Upcoming Catalysts
  • XmAb819READOUT
    Cash runway at this date: 20mo
    Oct 25, 20268d ago8-K
Phase Distribution
30 lead-sponsored trials·8 active·16 completed
Phase 122
Phase 1/23
Phase 25
(5 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 2
    Completed

    Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD)

    XmAb5871

    IgG4-RD

    Enrollment
    20
    Start
    Mar 2016
    Primary Completion
    Dec 2017
    Completion
    Dec 2017
    NCT02725476
  • Phase 2
    Completed

    A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus

    XmAb5871, Placebo to match XmAb5871

    Systemic Lupus Erythematosus

    Enrollment
    105
    Start
    Feb 2016
    Primary Completion
    Jul 2018
    Completion
    Jul 2018
    NCT02725515
  • Phase 2
    Completed

    XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

    vudalimab monotherapy

    Metastatic Castration-Resistant Prostate Cancer

    Enrollment
    72
    Start
    Oct 2021
    Primary Completion
    Jun 2025
    Completion
    Jun 2025
    NCT05005728
  • Phase 2
    Active, not recruiting

    A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

    vudalimab

    Ovarian Cancer, Clear Cell Carcinoma +3

    Enrollment
    170
    Start
    Jul 2022
    Primary Completion
    Oct 2025est.
    Completion
    Dec 2025est.
    NCT05032040
  • Phase 2
    Terminated

    Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)

    Plamotamab, Tafasitamab

    Diffuse Large-cell B-cell Lymphoma

    Enrollment
    3
    Start
    Apr 2022
    Primary Completion
    Feb 2023
    Completion
    Feb 2023
    NCT05328102
  • Phase 1/2
    Terminated

    Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer

    XmAb18087, XmAb18087 ± Pembrolizumab

    Merkel Cell Carcinoma, Small Cell Lung Cancer

    Enrollment
    4
    Start
    May 2021
    Primary Completion
    Mar 2022
    Completion
    Mar 2022
    NCT04590781
  • Phase 1/2
    Terminated

    Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC

    Vudalimab + Carboplatin + Pemetrexed, Pembrolizumab + Carboplatin + Pemetrexed

    Nonsquamous Non-small Cell Lung Cancer

    Enrollment
    28
    Start
    Dec 2023
    Primary Completion
    Dec 2025
    Completion
    Dec 2025
    NCT06173505
  • Phase 1/2
    Recruiting

    Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

    XmAb942, Placebo

    Ulcerative Colitis (UC)

    Enrollment
    270
    Start
    Oct 2024
    Primary Completion
    Dec 2027est.
    Completion
    May 2030est.
    NCT06619990
  • Phase 1
    Completed

    Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma

    XmAb2513

    Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma

    Enrollment
    23
    Start
    Dec 2007
    Primary Completion
    Apr 2010
    Completion
    Apr 2010
    NCT00606645
  • Phase 1
    Completed

    Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia

    XmAb5574

    Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

    Enrollment
    27
    Start
    Sep 2010
    Primary Completion
    Jan 2013
    Completion
    Jan 2013
    NCT01161511
  • Phase 1
    Completed

    Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis

    XmAb7195, Placebo

    Allergic Rhinitis, Allergic Conjunctivitis +1

    Enrollment
    72
    Start
    May 2014
    Primary Completion
    Sep 2015
    Completion
    Sep 2015
    NCT02148744
  • Phase 1
    Completed

    PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies

    XmAb14045

    Acute Myelogenous Leukemia, B-cell Acute Lymphoblastic Leukemia +2

    Enrollment
    120
    Start
    Aug 2016
    Primary Completion
    Sep 2021
    Completion
    Sep 2021
    NCT02730312
  • Phase 1
    Completed

    XmAb5871 Bioavailability Study

    XmAb5871

    Healthy Volunteers

    Enrollment
    50
    Start
    Jul 2016
    Primary Completion
    Oct 2016
    Completion
    Oct 2016
    NCT02867098
  • Phase 1
    Completed

    Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb®7195

    XmAb7195, Placebo

    Healthy Volunteers, Atopic Disease

    Enrollment
    57
    Start
    Aug 2016
    Primary Completion
    Feb 2017
    Completion
    Feb 2017
    NCT02881853
  • Phase 1
    Completed

    Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

    XmAb13676

    B-cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia

    Enrollment
    154
    Start
    Oct 2016
    Primary Completion
    Apr 2024
    Completion
    Apr 2024
    NCT02924402
  • Phase 1
    Completed

    A Study of XmAb®18087 in Subjects With NET and GIST

    XmAb18087

    Neuroendocrine Tumor, Gastrointestinal Neoplasm

    Enrollment
    62
    Start
    Jan 2018
    Primary Completion
    Oct 2021
    Completion
    Oct 2021
    NCT03411915
  • Phase 1
    Terminated

    Study Evaluating AMG 424 in Subjects With Multiple Myeloma

    AMG 424

    Relapsed/ Refractory Multiple Myeloma

    Enrollment
    27
    Start
    Jul 2018
    Primary Completion
    Jun 2020
    Completion
    Jun 2020
    NCT03445663
  • Phase 1
    Completed

    A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

    XmAb20717

    Melanoma, Breast Carcinoma +26

    Enrollment
    150
    Start
    Jul 2018
    Primary Completion
    Jun 2022
    Completion
    Sep 2022
    NCT03517488
  • Phase 1
    Completed

    A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

    XmAb®23104, Yervoy® (ipilimumab)

    Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma +14

    Enrollment
    198
    Start
    May 2019
    Primary Completion
    Feb 2024
    Completion
    Feb 2024
    NCT03752398
  • Phase 1
    Completed

    A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

    XmAb®22841, Pembrolizumab (Keytruda®)

    Melanoma, Cervical Carcinoma +21

    Enrollment
    78
    Start
    May 2019
    Primary Completion
    Feb 2023
    Completion
    Feb 2023
    NCT03849469
  • Phase 1
    Completed

    Safety, Tolerability and PK of a Single Subcutaneous Injection of XmAb27564 in Healthy Volunteers

    XmAb27564, Placebo

    Safety in Healthy Volunteers

    Enrollment
    48
    Start
    Apr 2021
    Primary Completion
    Nov 2022
    Completion
    Nov 2022
    NCT04857866
  • Phase 1
    Recruiting

    Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

    XmAb819

    Clear Cell Renal Cell Carcinoma

    Enrollment
    307
    Start
    Jun 2022
    Primary Completion
    Feb 2027est.READOUT
    Completion
    Dec 2028est.
    NCT05433142
  • Phase 1
    Completed

    Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

    XmAb®808, Keytruda® (pembrolizumab)

    Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma +7

    Enrollment
    60
    Start
    Dec 2022
    Primary Completion
    May 2025
    Completion
    May 2025
    NCT05585034
  • Phase 1
    Terminated

    A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors

    XmAb662, Keytruda® (pembrolizumab)

    Solid Tumors

    Enrollment
    7
    Start
    Jul 2023
    Primary Completion
    May 2024
    Completion
    May 2024
    NCT05996445
  • Phase 1
    Terminated

    Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis

    XmAb27564, Placebo

    Psoriasis, Atopic Dermatitis

    Enrollment
    23
    Start
    Oct 2022
    Primary Completion
    Mar 2024
    Completion
    Nov 2024
    NCT06005792

1-25 of 30

Search ClinicalTrials.gov for “Xencor”